Close Menu
Home › Curetis 2017 Revenues Down 8 Percent

Curetis 2017 Revenues Down 8 Percent

Apr 30, 2018
|
staff reporter

NEW YORK (GenomeWeb) – Curetis today posted an 8 percent year-over-year drop in 2017 revenues as an increase in sales of test cartridges for its Unyvero molecular diagnostic instrument was offset by a decline in system and service sales.

For the year ended Dec. 31, 2017, Curetis' revenues fell to €1.2 million ($1.4 million) from €1.3 million in 2016. Cartridge sales in 2017 were €736,000 versus €573,000 the year before, while instrument and service sales fell to €465,000 from €738,000.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
10
Featured Webinar

Laboratory Validation of a Kit-Based Liquid Biopsy NGS Assay

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

What's Popular?

In Molecular Diagnostics

  1. Bionano Genomics Commences Public Stock Offering

  2. Chinese Infectious Disease Dx Firm Vision Medicals Raises $14M in Series A Round

  3. Curetis Reports 36 Percent Increase in H1 Revenues

  4. Scope Fluidics Subsidiary Developing 15-Minute PCR System for POC Infectious Disease MDx

    Premium

  5. Inex Innovate to Launch New Molecular Tests for Ovarian Cancer, Breast Cancer in Asia

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.